- Gastroenterology Advisor

Gastric Malignancies


Latest Articles

FDA_drug approval

Ayvakit Approval for GI Stromal Tumor With PDGFRAM Mutation

The FDA has approved Ayvakit (avapritinib; Blueprint Medicines Corporation), a tyrosine kinase inhibitor, for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.